Neural Substrates of Treatment Response to Cognitive-Behavioral Therapy in Panic Disorder With Agoraphobia
Supplemental Material
1345_ds001.pdf (61 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×1345_ds001.pdf (61 KB)
Principal investigators with respective areas of responsibility in the MAC study are as follows: V. Arolt (overall MAC program coordination; Münster, Germany); H.U. Wittchen (principal investigator for the randomized clinical trial and manual development; Dresden, Germany); A. Hamm (principal investigator for psychophysiology; Greifswald, Germany); A.L. Gerlach (principal investigator for psychophysiology and panic subtypes; Münster, Germany); A. Ströhle (principal investigator for experimental pharmacology, Berlin); T. Kircher (principal investigator for functional neuroimaging; Marburg, Germany); and J. Deckert (principal investigator for genetics; Würzburg, Germany). Additional site directors in the randomized controlled trial component of the program are as follows: G.W. Alpers (Würzburg, Germany); T. Fydrich and L. Fehm (Berlin-Adlershof, Germany); and T. Lang (Bremen, Germany).
The study sites and staff members are as follows: Greifswald, Germany (coordinating site for psychophysiology): Christiane Melzig, Jan Richter, Susan Richter, and Matthias von Rad; Berlin-Charité, Germany (coordinating center for experimental pharmacology): Harald Bruhn, Anja Siegmund, Meline Stoy, and André Wittmann; Berlin-Adlershof, Germany: Irene Schulz; Münster, Germany (overall MAC program coordination, genetics, and functional neuroimaging): Andreas Behnken, Katharina Domschke, Adrianna Ewert, Carsten Konrad, Bettina Pfleiderer, Christina Uhlmann, and Peter Zwanzger; Münster, Germany (coordinating site for psychophysiology and subtyping): Judith Eidecker, Swantje Koller, Fred Rist, and Anna Vossbeck-Elsebusch; Marburg and Aachen, Germany (coordinating center for functional neuroimaging): Barbara Drüke, Sonja Eskens, Thomas Forkmann, Siegfried Gauggel, Susan Gruber, Andreas Jansen, Thilo Kellermann, Isabelle Reinhardt, and Nina Vercamer-Fabri; Dresden, Germany (coordinating site for data collection, analysis, and the randomized controlled trial): Franziska Einsle, Christine Froehlich, Andrew T. Gloster, Christina Hauke, Simone Heinze, Michael Hoefler, Ulrike Lueken, Peter Neudeck, Stephanie Preiss, and Dorte Westphal; University of Würzburg, Department of Psychiatry (coordinating center for genetics): Andreas Reif and Caro Gagel; University of Würzburg, Department of Psychology: Julia Duerner, Hedwig Eisenbarth, Antje B. M. Gerdes, Harald Krebs, Paul Pauli, Silvia Schad, and Nina Steinhäuser; Bremen, Germany: Veronika Bamann, Sylvia Helbig-Lang, Anne Kordt, Pia Ley, Franz Petermann, and Eva-Maria Schroeder. Additional support was provided by staff from the coordinating center for clinical studies in Dresden, Germany: Xina Graehlert and Marko Käppler.
The randomized controlled trial was approved by the Ethics Committee of the Medical Faculty of Technische Universität, Dresden, Germany (project number, EK 164082006). The neuroimaging components were approved by the Ethics Committee of the Medical Faculty of Rheinisch-Westfaehlische Hochschule University, Aachen, Germany (project number, EK 073/07), and at all local sites. The experimental pharmacology study was approved by the Ethics Committee of the state of Berlin (EudraCT, 2006-00-4860-29).